| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOSARTAN POTASSIUM | 219859 | 001 | ANDA | LOSARTAN POTASSIUM | TABLET;ORAL | 25MG | No | No | 2025/09/19 | 2025/09/19 | GRAVITI PHARMS | Prescription |
| LOSARTAN POTASSIUM | 219859 | 002 | ANDA | LOSARTAN POTASSIUM | TABLET;ORAL | 50MG | No | No | 2025/09/19 | 2025/09/19 | GRAVITI PHARMS | Prescription |
| LOSARTAN POTASSIUM | 219859 | 003 | ANDA | LOSARTAN POTASSIUM | TABLET;ORAL | 100MG | No | No | 2025/09/19 | 2025/09/19 | GRAVITI PHARMS | Prescription |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | 219869 | 001 | ANDA | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | TABLET;ORAL | 12.5MG;50MG | No | No | 2026/05/27 | -- | HETERO LABS LTD V | Prescription |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | 219869 | 002 | ANDA | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | TABLET;ORAL | 12.5MG;100MG | No | No | 2026/05/27 | -- | HETERO LABS LTD V | Prescription |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | 219869 | 003 | ANDA | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | TABLET;ORAL | 25MG;100MG | No | No | 2026/05/27 | -- | HETERO LABS LTD V | Prescription |